BMRN:NASDAQ
Biomarin Pharmaceutical Inc
$64.63
arrow_downward
-2.86%(-1.90) 1D
$65.15
arrow_upward
+0.80% (+0.52)bedtimeAfter hours
Closed: Sep 8, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
$65.24
High
$66.26
Low
$64.01
Mkt. cap
12.51B
Avg. vol.
2.15M
Volume
1.46M
P/E ratio
174.24
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.24
Shares outstanding
193.57M
No. of employees
3K
Open
$65.24
High
$66.26
Low
$64.01
Mkt. cap
12.51B
Avg. vol.
2.15M
Volume
1.46M
P/E ratio
174.24
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.24
Shares outstanding
193.57M
No. of employees
3K
News stories
From web sources and news partners
Simply Wall Street
·
10 hours ago
Royalty Deal Could Be A Big Development For BioMarin Stock (BMRN)
StockStory
·
1 day ago
3 Reasons to Avoid BMRN and 1 Stock to Buy Instead
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3.22K
FoundedMar 1997
HeadquartersSan Rafael, California, United States
SectorBiotechnology
Websitebiomarin.com